Literature DB >> 29181179

Efficacy of bendamustine on thrombocytopenia and hemolytic anemia secondary to CD5-positive B-cell lymphoma with massive splenomegaly in a patient with rheumatoid arthritis.

Yuzuru Hosoda1,2, Hiroshi Hagino3, Norihiko Hino2, Toru Motokura1,2.   

Abstract

Chemotherapy for lymphoma may be avoided in the presence of coincident cytopenia. In case of immune cytopenia secondary to lymphoma, treatment of cytopenia is the same for primary cases, however, chemotherapy for lymphoma may be effective at the cost of severe hematological toxicity. The present study reports a complex case of thrombocytopenia and direct antiglobulin test-negative hemolytic anemia, thus mimicking Evans syndrome, secondary to cluster of differentiation 5-positive B-cell lymphoma with massive splenomegaly, in a patient suffering from rheumatoid arthritis for two decades. Treatment with prednisolone, high-dose dexamethasone, eltrombopag and rituximab for cytopenia were not effective. Chemotherapy with bendamustine subsequently resolved the cytopenia, additionally resulting in a complete remission of lymphoma. Thus, bendamustine may have a role in the management of lymphoma complicated with severe cytopenia.

Entities:  

Keywords:  Evans syndrome; bendamustine; immune thrombocytopenia; rheumatoid arthritis; splenomegaly

Year:  2017        PMID: 29181179      PMCID: PMC5700260          DOI: 10.3892/mco.2017.1425

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  11 in total

1.  Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Authors:  Ken Ohmachi; Nozomi Niitsu; Toshiki Uchida; Seok Jin Kim; Kiyoshi Ando; Naoki Takahashi; Naoto Takahashi; Naokuni Uike; Hyeon Seok Eom; Yee Soo Chae; Takashi Terauchi; Ukihide Tateishi; Mitsuaki Tatsumi; Won Seog Kim; Kensei Tobinai; Cheolwon Suh; Michinori Ogura
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

2.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Authors:  Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger
Journal:  Lancet       Date:  2013-02-20       Impact factor: 79.321

3.  Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.

Authors:  Felicitas Hitz; Emanuele Zucca; Thomas Pabst; Natalie Fischer; Anne Cairoli; Panagiotis Samaras; Clemens B Caspar; Nicolas Mach; Fatime Krasniqi; Adrian Schmidt; Christian Rothermundt; Milica Enoiu; Katrin Eckhardt; Simona Berardi Vilei; Stephanie Rondeau; Ulrich Mey
Journal:  Br J Haematol       Date:  2016-03-28       Impact factor: 6.998

4.  Malignant lymphoma-associated autoimmune diseases--a descriptive epidemiological study.

Authors:  László Váróczy; Lajos Gergely; Margit Zeher; Gyula Szegedi; Arpád Illés
Journal:  Rheumatol Int       Date:  2002-08-29       Impact factor: 2.631

5.  How I diagnose and treat splenic lymphomas.

Authors:  Emilio Iannitto; Claudio Tripodo
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

6.  Intravascular lymphomatosis presenting in the lung.

Authors:  S A Yousem; T V Colby
Journal:  Cancer       Date:  1990-01-15       Impact factor: 6.860

7.  Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study.

Authors:  M Fallah; X Liu; J Ji; A Försti; K Sundquist; K Hemminki
Journal:  Ann Oncol       Date:  2014-07-31       Impact factor: 32.976

8.  The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases.

Authors:  Marc Michel; Valérie Chanet; Agnès Dechartres; Anne-Sophie Morin; Jean-Charles Piette; Lorenzo Cirasino; Giovanni Emilia; Francesco Zaja; Marco Ruggeri; Emmanuel Andrès; Philippe Bierling; Bertrand Godeau; Francesco Rodeghiero
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

9.  A Case of Non-Hodgkin's Lymphoma in Patient with Coombs' Negative Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura.

Authors:  So Yeon Park; Soyon Kim; Eun Sil Kim; Soon Uk Choi; Hee Jae Hyun; Ju Young Ahn; Ju Hyoung Lee; Seo Hee Ryu; Jae Hyun Park; Gyeong In Lee; Hyo Jin Lee
Journal:  Cancer Res Treat       Date:  2012-03-31       Impact factor: 4.679

10.  Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year.

Authors:  Shizuka Nishii-Ito; Hiroki Izumi; Hirokazu Touge; Kenichi Takeda; Yuzuru Hosoda; Akira Yamasaki; Satoshi Kuwamoto; Eiji Shimizu; Toru Motokura
Journal:  Mol Clin Oncol       Date:  2016-10-26
View more
  1 in total

Review 1.  Treatment of Secondary Immune Thrombocytopenia with Non-Hodgkin Lymphoma: A Case Report and Literature Review.

Authors:  Yuya Kurihara; Kazuki Taoka; Eri Takagi; Kazuhiro Toyama; Kumi Nakazaki; Mineo Kurokawa
Journal:  Intern Med       Date:  2021-05-15       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.